NCT02680379

Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome

A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Université de Sherbrooke · Academic / Other
• Sex: All
• Age: 8 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.

Conditions

• Fragile X Syndrome

Interventions

Type	Name	Description
DRUG	Minocycline, then Minocycline/Lovastatin	Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
DRUG	Lovastatin, then Minocycline/Lovastatin	Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-10-01
• Completion: 2017-11-01
• First posted: 2016-02-11
• Last updated: 2018-10-15

Locations

1 site across 1 country: Canada